NEW YORK (GenomeWeb) – Progenity said today that it has acquired proteomic diagnostic company Carmenta Bioscience.

A spin-out of Stanford University, Carmenta is focused on developing a protein-based test for preeclampsia, a hypertensive disorder of pregnancy. Preeclampsia is a leading cause of preterm births and maternal fetal deaths, with between 5 and 8 percent of pregnant women developing the condition.

Under the terms of the acquisition, Carmenta CEO Matthew Cooper will join Progenity as chief scientific officer.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.